XM does not provide services to residents of the United States of America.
V
V

Vertex

News

Beam Therapeutics falls after patient death in early trial

BUZZ-Beam Therapeutics falls after patient death in early trial ** Shares of biotech firm Beam Therapeutics BEAM.O fall 3.30% to $23.56 ** A patient with sickle cell disease has died due to respiratory failure in an early-to-mid stage trial of company's CRISPR-based cell therapy, BEAM-101, according to an abstract ** Respiratory failure was likely
V

Vertex Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Vertex Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary Vertex Pharmaceuticals Inc VRTX.OQ reported quarterly adjusted earnings of $4.38​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $4.08. The mean expectation of twenty nine analysts for the quarter was for earnings of $4.14 per share.
V

U.S. Celanese Corporation, Disc Medicine, Editas Medicine

U.S. RESEARCH ROUNDUP-Celanese Corporation, Disc Medicine, Editas Medicine Nov 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Celanese Corporation, Disc Medicine and Editas Medicine, on Tuesday. HIGHLIGHTS * Affiliated Managers Group Inc AMG.N : TD Cowen cuts to hold from buy * Celanese Corporation CE.N : Wells Fargo cuts to equal weight from overweight * Disc Medicine Inc IRON.O : Raymond James raises to strong b
A
A
B
C
C
E
H
I
M
V
W
E
F
B
C

Vertex Pharmaceuticals Q3 Operating Income USD 1,116.3 Million

BRIEF-Vertex Pharmaceuticals Q3 Operating Income USD 1,116.3 Million Nov 04 (Reuters) - Vertex Pharmaceuticals Q3 net income USD 1,045.4 million. Q3 revenue USD 2,771.9 million vs. IBES estimate USD 2,724 million outlook FY product revenue USD 10,800-10,900 million
V

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength Nov 4 (Reuters) - Vertex Pharmaceuticals VRTX.O raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion.
V

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.